Resource Type

Journal Article 16

Year

2023 1

2022 1

2021 3

2020 3

2017 2

2016 2

2015 1

2012 1

open ︾

Keywords

SARS-CoV-2 3

COVID-19 2

neutralizing antibody 2

-acetylglucosamine 1

Nsp9 1

γ3 1

Antibody–drug conjugate 1

Antigen 1

B-cell acute lymphoblastic leukemia 1

B7-H3 1

Bactrian camel 1

Bispecific antibody 1

CD19 1

CD20 1

China 1

Conjugate vaccine 1

Ebola virus 1

Efficacy 1

Env conformational states 1

GP I bα 1

open ︾

Search scope:

排序： Display mode:

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Qian Wang, Linqi Zhang

Frontiers of Medicine 2020, Volume 14, Issue 1,   Pages 30-42 doi: 10.1007/s11684-019-0721-9

Abstract: Recent discoveries in broadly neutralizing monoclonal antibodies (bNAbs) has led to the development of

Keywords： HIV-1     broadly neutralizing antibodies     Env conformational states     vaccine design     SOSIP    

HTML PDF Collect

Human monoclonal antibodies as candidate therapeutics against emerging viruses

Yujia Jin, Cheng Lei, Dan Hu, Dimiter S. Dimitrov, Tianlei Ying

Frontiers of Medicine 2017, Volume 11, Issue 4,   Pages 462-470 doi: 10.1007/s11684-017-0596-6

Abstract: Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer

Keywords： human monoclonal antibodies     emerging infectious diseases     SARS-CoV     MERS-CoV     Ebola virus    

HTML PDF Collect

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in

Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 149-159 doi: 10.1007/s11684-020-0764-y

Abstract: Moreover, designing a universal influenza vaccine that is sufficiently immunogenic to induce universal antibodieshidden in the hemagglutinin (HA) trimeric interface have been discovered recently, and a number of antibodiesIn this review, we focused on the antibodies targeting these newly discovered epitopes in the HA domainof the influenza virus to promote the development of universal anti-influenza antibodies or vaccines

Keywords： influenza virus     neutralizing antibody     hemagglutinin     globular head region     trimeric interface    

HTML PDF Collect

Synthesis of haptens and production of antibodies to bisphenol A

Xiya ZHANG, Xiaoyun DONG, Sijun ZHAO, Yuebin KE, Kai WEN, Suxia ZHANG, Zhanhui WANG, Jianzhong SHEN

Frontiers of Agricultural Science and Engineering 2017, Volume 4, Issue 3,   Pages 366-372 doi: 10.15302/J-FASE-2017132

Abstract: bisphenol A (BPA), including two new haptens, were used to produce highly sensitive and specific polyclonal antibodiesHighly sensitive polyclonal antibodies were obtained and characterized using indirect competitive enzyme-linked

Keywords： bisphenol A     cross-reactivity     hapten     indirect competitive ELISA     polyclonal antibody    

HTML PDF Collect

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 746-751 doi: 10.1007/s11684-020-0822-5

Abstract: Here we examined, using ELISA, the IgG antibodies in serum specimens collected from 17 COVID-19 patients

Keywords： SARS-CoV-2     neutralizing antibodies     T-cell response    

HTML PDF Collect

Characterization of polyclonal antibodies against nonstructural protein 9 from the porcine reproductive

Mengmeng ZHAO,Juanjuan QIAN,Jiexiong XIE,Tiantian CUI,Songling FENG,Guoqiang WANG,Ruining WANG,Guihong ZHANG

Frontiers of Agricultural Science and Engineering 2016, Volume 3, Issue 2,   Pages 153-160 doi: 10.15302/J-FASE-2016097

Abstract: Antibodies against 9 will be of great importance for the diagnosis and treatment of the causal agentA study was undertaken to generate polyclonal antibodies against the immunodominant 9.

Keywords： PRRSV     Nsp9     expression     antibody     neutralize    

HTML PDF Collect

The biopharmaceutical industry in China: history and future perspectives

Kai Gao, Junzhi Wang

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 101-111 doi: 10.1007/s11684-012-0191-9

Abstract:

Biopharmaceuticals reflect the rapid progress achieved in modern biomedical research. This area has also become one of the main criteria for assessing the development level of biotechnology for a particular country. Although it has been only three decades since the first biopharmaceutical, recombinant human insulin, was licensed by the US Food and Drug Administration, the biopharmaceutical industry has become the fastest growing, most dynamic and technology-intensive sector in the biomedical field. Since the licensing of recombinant human interferon α1b in 1989, the biopharmaceutical industry in China has gone through initial developments and gradually entered a period of rapid growth. This paper provides an overview of the status and development trends of biopharmaceuticals in China, and compares them with those observed in developed countries.

Keywords： biopharmaceuticals     antibodies     market trends     diseases     China     national regulatory agency    

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: that promote anti-tumor immunity have recently been developed, such as small molecules, bispecific antibodiesBispecific antibodies, which bind two different antigens or one antigen with two different epitopes,

Keywords： cancer immunotherapy     bispecific antibodies     small molecules     chimeric antigen receptor T therapy     cancer    

HTML PDF Collect

Anti-β glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two

Wenjing Zhang,Fei Gao,Donghe Lu,Na Sun,Xiaoxue Yin,Meili Jin,Yanhong Liu

Frontiers of Medicine 2016, Volume 10, Issue 1,   Pages 76-84 doi: 10.1007/s11684-015-0426-7

Abstract:

Anti-β2 glycoprotein I (anti-β2GP I ) antibodies are importantHowever, the mechanism by which anti-β2GP I antibodies are involved in the pathogenesisIn this report, we investigated the role of anti-β2GP I antibodies in complexes with

Keywords： anti-β2GP I /β2GP I complex     platelet     GP I bα     apoER2'     thrombosis    

HTML PDF Collect

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Frontiers of Medicine 2021, Volume 15, Issue 4,   Pages 644-648 doi: 10.1007/s11684-021-0847-4

Abstract: Currently, the receptor-binding domain (RBD) of the spike (S) protein is the main target of neutralizing antibodiesThus, a cocktail therapy combining two or more antibodies that recognize different regions of the viral

Keywords： neutralizing antibody     antibody cocktail     SARS-CoV-2     COVID-19     therapeutic strategy    

HTML PDF Collect

Passive antibody therapy in emerging infectious diseases

Frontiers of Medicine doi: 10.1007/s11684-023-1021-y

Abstract: Antibody therapies encompassing convalescent plasma, hyperimmunoglobulin, and neutralizing monoclonal antibodies

Keywords： SARS-CoV-2     COVID-19     convalescent plasma     hyperimmunoglobulin     neutralizing monoclonal antibodies    

HTML PDF Collect

Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial

Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,

Engineering doi: 10.1016/j.eng.2023.09.012

Abstract: PNAG-based vaccines and PNAG-targeting antibodies have shown great efficacy in preclinical research.Furthermore, clinical tests for both vaccines and antibodies have been carried out in humans and economically

Keywords： Poly-     N     -acetylglucosamine     Conjugate vaccine     Monoclonal antibody    

HTML PDF Collect

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: Here, we design and characterize two novel antibodies, A-319 and A-2019.Blinatumomab and A-319 are CD3/CD19 bispecific antibodies with different molecular sizes and structures

Keywords： B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

HTML PDF Collect

A comprehensive analysis of immunoglobulin heavy chain genes in the Bactrian camel (

Zuoxiang LIANG,Tao WANG,Yi SUN,Wenlong YANG,Zhihong LIU,Jing FEI,Ying GUO,Qingwei MA,Qingjie PAN,Liming REN

Frontiers of Agricultural Science and Engineering 2015, Volume 2, Issue 3,   Pages 249-259 doi: 10.15302/J-FASE-2015056

Abstract: Heavy chain only antibodies (HCAbs) represent a rare type of antibody that is devoid of light chainsAdditionally, the variable region of HCAbs (VHH) and the conventional antibodies (VH) sequences associated

Keywords： Bactrian camel     heavy-chain antibodies     VHH     γ3    

HTML PDF Collect

Modified Therapeutic Antibodies: Improving Efficacy Review

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Engineering 2021, Volume 7, Issue 11,   Pages 1529-1540 doi: 10.1016/j.eng.2020.06.030

Abstract: prosperity of the biotherapeutics market reflects the feasibility and effectiveness of therapeutic antibodiesimpeded binding, reduced effector functions, and frequent adverse reactions, modifications of therapeutic antibodiesof variable region fragment (scFv) for chimeric antigen receptor T (CAR-T) cells; and ⑥ bispecific antibodiesThis review recapitulates the international progress that has been achieved with modified therapeutic antibodies

Keywords： Therapeutic antibody     Modification     Efficacy     Antigen     Antibody–drug conjugate     Bispecific antibody    

HTML PDF Collect

Title Author Date Type Operation

Broadly neutralizing antibodies and vaccine design against HIV-1 infection

Qian Wang, Linqi Zhang

Journal Article

Human monoclonal antibodies as candidate therapeutics against emerging viruses

Yujia Jin, Cheng Lei, Dan Hu, Dimiter S. Dimitrov, Tianlei Ying

Journal Article

Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in

Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying

Journal Article

Synthesis of haptens and production of antibodies to bisphenol A

Xiya ZHANG, Xiaoyun DONG, Sijun ZHAO, Yuebin KE, Kai WEN, Suxia ZHANG, Zhanhui WANG, Jianzhong SHEN

Journal Article

Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection

Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen

Journal Article

Characterization of polyclonal antibodies against nonstructural protein 9 from the porcine reproductive

Mengmeng ZHAO,Juanjuan QIAN,Jiexiong XIE,Tiantian CUI,Songling FENG,Guoqiang WANG,Ruining WANG,Guihong ZHANG

Journal Article

The biopharmaceutical industry in China: history and future perspectives

Kai Gao, Junzhi Wang

Journal Article

Emerging immunological strategies: recent advances and future directions

Journal Article

Anti-β glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two

Wenjing Zhang,Fei Gao,Donghe Lu,Na Sun,Xiaoxue Yin,Meili Jin,Yanhong Liu

Journal Article

Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections

Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie

Journal Article

Passive antibody therapy in emerging infectious diseases

Journal Article

Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial

Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,

Journal Article

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies

Journal Article

A comprehensive analysis of immunoglobulin heavy chain genes in the Bactrian camel (

Zuoxiang LIANG,Tao WANG,Yi SUN,Wenlong YANG,Zhihong LIU,Jing FEI,Ying GUO,Qingwei MA,Qingjie PAN,Liming REN

Journal Article

Modified Therapeutic Antibodies: Improving Efficacy

Ji-Min Dai, Xue-Qin Zhang, Jing-Yao Dai, Xiang-Min Yang, Zhi-Nan Chen

Journal Article